Collegium Pharmaceutical Stock Investor Sentiment
| COLL Stock | USD 29.67 0.21 0.71% |
About 53% of Collegium Pharmaceutical's investor base is interested to short. The analysis of overall sentiment of trading Collegium Pharmaceutical stock suggests that many investors are impartial at this time. Collegium Pharmaceutical's investing sentiment shows overall attitude of investors towards Collegium Pharmaceutical.
Comfort Level 47
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Collegium Pharmaceutical's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Collegium Pharmaceutical.
News SentimentNeutral | Hype SentimentNeutral | Insider SentimentDisposing |
Collegium Historical Sentiment
Although Collegium Pharmaceutical's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Collegium, such as negative comments on social media and news outlets, may cause fear in the market and push Collegium Pharmaceutical's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Collegium.
Collegium |
Collegium Pharmaceutical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Collegium Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Collegium Pharmaceutical that are available to investors today. That information is available publicly through Collegium media outlets and privately through word of mouth or via Collegium internal channels. However, regardless of the origin, that massive amount of Collegium data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Collegium Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Collegium Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Collegium Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Collegium Pharmaceutical alpha.
Collegium Pharmaceutical Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Improved Revenues Required Before Collegium Pharmaceutical, Inc. Shares Find Their Feet | 12/24/2024 |
2 | Disposition of 25149 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 30.52 subject to Rule 16b-3 | 02/10/2025 |
3 | Rubric Capital Management LP Increases Stake in Collegium Pharmaceutical Inc | 02/14/2025 |
4 | Is Collegium Pharmaceutical, Inc.s 38 percent ROE Better Than Average | 02/27/2025 |
5 | Collegium Pharmaceutical Q4 Earnings Taking a Look at Key Metrics Versus Estimates | 02/28/2025 |
6 | Acquisition by Heffernan Michael Thomas of 4820 shares of Collegium Pharmaceutical subject to Rule 16b-3 | 03/03/2025 |
7 | Collegium Pharmaceutical, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts | 03/04/2025 |
8 | Disposition of 20000 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 28.0264 subject to Rule 16b-3 | 03/05/2025 |
9 | Collegium Recommends Calcutta High Court Judges Elevation To Top Court | 03/06/2025 |
10 | Collegium Pharmaceutical, Inc. EVP Shirley R. Kuhlmann Sells 26,067 Shares of Stock | 03/07/2025 |
11 | Disposition of 10445 shares by Colleen Tupper of Collegium Pharmaceutical at 30.006 subject to Rule 16b-3 | 03/11/2025 |
Check out Collegium Pharmaceutical Hype Analysis, Collegium Pharmaceutical Correlation and Collegium Pharmaceutical Performance. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Earnings Share 1.86 | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.